ReviewArchives of medical science : AMS2026
Hypertension and ovarian cancer risk: a meta-analysis of observational studies.
Review in Archives of medical science : AMS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ovarian cancer is the eighth most common cancer among women and an important cause of cancer-related mortality, particularly in high-income countries. Scientific studies show that hypertension may play a significant role in the initiation of cancer. Therefore, we conducted the first meta-analysis to comprehensively examine the association between hypertension and ovarian cancer risk. Material and methods: We performed a literature search of all of the observational studies published as original articles from inception to July 2024, and we searched the following electronic databases: PubMed, Embase, and Cochrane Library. Finally, we included ten full-text cohort and case-control studies addressing the effect of hypertension on ovarian cancer in this meta-analysis. Our study was preregistered with International Prospective Register of Systematic Reviews (PROSPERO CRD42024565574) and followed the PRISMA statement. Effect size was presented as risk ratios (RRs) and 95% confidence intervals (CIs). Heterogeneity test evaluation was performed using Cochran's Q test and Results: The meta-analysis included a total of 2,497,898 women. There was a statistically significant association (RR = 1.10, 95% CI: 1.02-1.23, Conclusions: The findings of this comprehensive review and meta-analysis indicate that hypertension is associated with higher overall risk of ovarian cancer. While the present data provide novel evidence, further prospective studies are needed to elucidate the association between hypertension and ovarian cancer risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.